ArticleTranslational lung cancer research2025
Patients' survival outcomes in clinical stage IA lung adenocarcinoma not affected by preoperative staging brain magnetic resonance imaging.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The necessity of conducting preoperative staging brain magnetic resonance imaging (MRI) for patients diagnosed with clinical stage IA lung adenocarcinoma (LUAD) is still a topic of discussion. The objective of this study was to explore the impact of staging brain MRI on survival outcomes in patients with clinical stage IA LUAD. Methods: Patients diagnosed with clinical stage IA LUAD who received curative surgical treatment from May 2005 to December 2018 was selected for this analysis. To account for potential confounding variables, propensity score matching (PSM) was utilized. Survival outcomes including overall survival (OS) over a period of 10 years, 10-year recurrence-free survival (RFS), and 10-year brain metastasis-specific RFS were evaluated. Multivariate Cox regression analysis was conducted to determine the relationship between staging brain MRI and the evaluated survival outcomes. Results: Of 593 clinical stage IA LUAD patients, 372 (median age: 57 years; 218 females) were recruited after dealing with confounding factors via PSM. No significant differences were found in 10-year OS, 10-year overall RFS and 10-year brain metastases-specific RFS between the group with and without staging brain MRI (all P>0.05). Multivariate analysis revealed that staging brain MRI was not associated with a significant improvement in OS [hazard ratio (HR), 2.35; 95% confidence interval (CI): 0.21-26.68; P=0.49], overall RFS (HR, 1.32; 95% CI: 0.75-2.31; P=0.33) or brain metastases-specific RFS (HR, 1.52; 95% CI: 0.60-3.84; P=0.38). Conclusions: For patients with clinical stage IA LUAD undergoing surgery, routine staging brain MRI may did not improve survival, suggesting that selective rather than universal use may be more appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.